Notice: This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends SBOT vs. KMDA, ETON, CRVS, SAGE, TNGX, NGNE, OLMA, AQST, RVNC, and TRVIShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Kamada (KMDA), Eton Pharmaceuticals (ETON), Corvus Pharmaceuticals (CRVS), Sage Therapeutics (SAGE), Tango Therapeutics (TNGX), Neurogene (NGNE), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), Revance Therapeutics (RVNC), and Trevi Therapeutics (TRVI). These companies are all part of the "medical" sector. Stellar Biotechnologies vs. Kamada Eton Pharmaceuticals Corvus Pharmaceuticals Sage Therapeutics Tango Therapeutics Neurogene Olema Pharmaceuticals Aquestive Therapeutics Revance Therapeutics Trevi Therapeutics Stellar Biotechnologies (NASDAQ:SBOT) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Does the MarketBeat Community believe in SBOT or KMDA? Kamada received 87 more outperform votes than Stellar Biotechnologies when rated by MarketBeat users. However, 66.48% of users gave Stellar Biotechnologies an outperform vote while only 65.91% of users gave Kamada an outperform vote. CompanyUnderperformOutperformStellar BiotechnologiesOutperform Votes23466.48% Underperform Votes11833.52% KamadaOutperform Votes32165.91% Underperform Votes16634.09% Do analysts prefer SBOT or KMDA? Kamada has a consensus target price of $14.50, suggesting a potential upside of 113.24%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Stellar Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stellar Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kamada 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, SBOT or KMDA? Kamada has higher revenue and earnings than Stellar Biotechnologies. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStellar Biotechnologies$210K472.34-$5.03M-$1.76-10.57Kamada$158.38M2.47$8.28M$0.2824.29 Does the media refer more to SBOT or KMDA? In the previous week, Kamada had 3 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 3 mentions for Kamada and 0 mentions for Stellar Biotechnologies. Kamada's average media sentiment score of 0.22 beat Stellar Biotechnologies' score of 0.00 indicating that Kamada is being referred to more favorably in the news media. Company Overall Sentiment Stellar Biotechnologies Neutral Kamada Neutral Do institutionals & insiders hold more shares of SBOT or KMDA? 1.7% of Stellar Biotechnologies shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 7.8% of Stellar Biotechnologies shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is SBOT or KMDA more profitable? Kamada has a net margin of 9.92% compared to Stellar Biotechnologies' net margin of -1,782.64%. Kamada's return on equity of 6.30% beat Stellar Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Stellar Biotechnologies-1,782.64% -51.12% -48.37% Kamada 9.92%6.30%4.49% SummaryKamada beats Stellar Biotechnologies on 15 of the 17 factors compared between the two stocks. Ad StocksToTradeLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!Click here to review Tim’s special offer before it’s too late. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.19M$6.63B$5.24B$9.02BDividend YieldN/A2.91%5.30%4.17%P/E Ratio-10.5710.4987.6517.23Price / Sales472.34202.371,083.84141.85Price / CashN/A57.1143.3337.88Price / Book8.785.175.195.13Net Income-$5.03M$153.18M$121.58M$227.03M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$18.61-18.7%N/A+414.4%$99.19M$210,000.00-10.5725Gap DownHigh Trading VolumeKMDAKamada4.2854 of 5 stars$5.97+0.8%$14.50+142.9%+14.3%$343.16M$158.38M21.32360News CoverageETONEton Pharmaceuticals2.9964 of 5 stars$13.04-0.1%$15.00+15.0%+176.3%$339.71M$34.68M-59.2720Analyst ForecastCRVSCorvus Pharmaceuticals2.5544 of 5 stars$5.24+0.6%$12.83+144.9%+179.1%$336.71MN/A-5.6330Analyst RevisionNews CoverageGap UpSAGESage Therapeutics4.4356 of 5 stars$5.45-1.6%$11.53+111.5%-72.1%$333.39M$106.40M-0.98690Gap DownTNGXTango Therapeutics2.183 of 5 stars$3.10-0.6%$13.14+324.0%-62.2%$333.00M$43.38M-2.6390Positive NewsNGNENeurogene3.138 of 5 stars$22.27-3.0%$60.83+173.2%-4.7%$330.82M$925,000.000.0090Gap DownOLMAOlema Pharmaceuticals2.253 of 5 stars$5.65-8.1%$27.00+377.9%-53.6%$323.73MN/A-2.5880AQSTAquestive Therapeutics2.3609 of 5 stars$3.52flat$11.00+212.5%+37.6%$320.95M$58.90M-7.82160Positive NewsRVNCRevance Therapeutics4.1621 of 5 stars$3.06flat$8.39+174.0%-59.2%$319.43M$256.95M-1.59597Analyst ForecastNews CoverageTRVITrevi Therapeutics3.0131 of 5 stars$4.10-4.0%$9.31+127.1%+208.3%$315.15MN/A-9.3220Positive News Related Companies and Tools Related Companies KMDA Competitors ETON Competitors CRVS Competitors SAGE Competitors TNGX Competitors NGNE Competitors OLMA Competitors AQST Competitors RVNC Competitors TRVI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SBOT) was last updated on 1/8/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredDonald Trump to Repeal Executive Order #14110?Nvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
